Androgen receptor isoforms expression in benign prostatic hyperplasia and primary prostate cancer.
Androgen receptor isoforms expression in benign prostatic hyperplasia and primary prostate cancer.
复制标题
DOI：
10.1371/journal.pone.0200613
复制
发表时间：
2018
期刊：
影响因子：
3.7
通讯作者：
Brum IS
中科院分区：
文献类型：
--
作者：
Hillebrand AC;Pizzolato LS;Neto BS;Branchini G;Brum IS
雄激素受体（AR）的分子变化作为AR变异体（AR- vs）在良性前列腺增生（BPH）和hormone-naïve前列腺癌的病理生理中所起的作用尚不清楚。本研究的目的是确定良性组织和原发性前列腺癌中AR异构体的存在，并评估其与原发性前列腺癌肿瘤侵袭性和生化复发的可能关联。RT-qPCR检测全长AR （AR- fl）和AR- v (AR- v1、AR- v4和AR- v7) mRNA水平。免疫组化（IHC） H-Score评价AR-FL （AR-CTD和AR-NTD）和AR-V7蛋白表达。所有研究的mRNA靶点在BPH和PCa中均有表达。两组AR-FL mRNA水平相似。AR-V4 mRNA在BPH中表达较高，AR-V1和AR-V7 mRNA在PCa中表达较高。AR-V7蛋白在两组的H-Score相似，而AR-CTD和AR-NTD在BPH上皮细胞的细胞核中较高。这些结果支持了这样的假设，即这些构成活性的AR亚型参与了原发性前列腺癌和前列腺增生的病理生理。ar - v在不同类型前列腺肿瘤中的作用及其可能受类固醇组织水平的调节需要阐明，以帮助指导这些疾病的最佳临床管理。
The role of molecular changes in the androgen receptor (AR) as AR variants (AR-Vs) is not clear in the pathophysiology of benign prostatic hyperplasia (BPH) and hormone-naïve PCa. The aim of the current work was to identify the presence of AR isoforms in benign tissue and primary PCa, and to evaluate the possible association with tumor aggressiveness and biochemical recurrence in primary PCa. The mRNA levels of full length AR (AR-FL) and AR-Vs (AR-V1, AR-V4 and AR-V7) were measured using RT-qPCR. The protein expression of AR-FL (AR-CTD and AR-NTD) and AR-V7 were evaluated by the H-Score in immunohistochemistry (IHC). All investigated mRNA targets were expressed both in BPH and PCa. AR-FL mRNA levels were similar in both groups. AR-V4 mRNA expression showed higher levels in BPH, and AR-V1 and AR-V7 mRNA expression were higher in PCa. The AR-V7 protein showed a similar H-Score in both groups, while AR-CTD and AR-NTD were higher in nuclei of epithelial cells from BPH. These results support the assumption that these constitutively active isoforms of AR are involved in the pathophysiology of primary PCa and BPH. The role of AR-Vs and their possible modulation by steroid tissue levels in distinct types of prostate tumors needs to be elucidated to help guide the best clinical management of these diseases.
登录
查看更多内容
影响因子：
23.4
作者：
Welti, Jonathan;Rodrigues, Daniel Nava;Sharp, Adam;Sun, Shihua;Lorente, David;Riisnaes, Ruth;Figueiredo, Ines;Zafeiriou, Zafeiris;Rescigno, Pasquale;de Bono, Johann S.;Plymate, Stephen R.
通讯作者：
Plymate, Stephen R.
影响因子：
64.5
作者：
Cancer Genome Atlas Research Network
通讯作者：
Cancer Genome Atlas Research Network
影响因子：
11.4
作者：
Lin, HK;Wang, L;Chang, CS
通讯作者：
Chang, CS
影响因子：
6.6
作者：
MIYAMOTO, KK;MCSHERRY, SA;MOHLER, JL
通讯作者：
MOHLER, JL
DOI：
10.1056/nejmoa1315815
发表时间：
2014-09-11
期刊：
The New England journal of medicine
影响因子：
--
作者：
Antonarakis ES;Lu C;Wang H;Luber B;Nakazawa M;Roeser JC;Chen Y;Mohammad TA;Chen Y;Fedor HL;Lotan TL;Zheng Q;De Marzo AM;Isaacs JT;Isaacs WB;Nadal R;Paller CJ;Denmeade SR;Carducci MA;Eisenberger MA;Luo J
通讯作者：
Luo J